Evome Medical Technologies Inc.
LNDZF · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $10 | $11 | $12 | $16 |
| % Growth | -5% | -12.7% | -23.2% | – |
| Cost of Goods Sold | $6 | $7 | $8 | $10 |
| Gross Profit | $4 | $3 | $4 | $6 |
| % Margin | 35.6% | 31.5% | 32.5% | 35.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $5 | $6 |
| SG&A Expenses | $3 | $4 | $5 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $1 | -$2 | -$0 |
| Operating Expenses | $4 | $5 | $4 | $6 |
| Operating Income | -$0 | -$1 | $0 | $0 |
| % Margin | -4.6% | -11.4% | 0% | 0% |
| Other Income/Exp. Net | -$1 | -$1 | -$4 | -$16 |
| Pre-Tax Income | -$1 | -$2 | -$4 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$2 | -$4 | -$16 |
| % Margin | -11.5% | -21.7% | -35.5% | -100.6% |
| EPS | 0 | 0 | 0 | -0.209 |
| % Growth | – | – | 100% | – |
| EPS Diluted | 0 | 0 | 0 | -0.209 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 57 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 57 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $1 | $1 |
| Depreciation & Amortization | $2 | $0 | $0 | -$1 |
| EBITDA | $1 | -$1 | -$3 | -$13 |
| % Margin | 11.6% | -13% | -21.6% | -84.5% |